Trinity Capital Inc. (NYSE: TRIN) has provided a senior secured term loan facility of up to $60m to Nasdaq-listed Codexis, Inc. (Nasdaq: CDXS), a provider of enzymatic solutions for therapeutics manufacturing.
The Phoenix, Arizona-based private credit manager and business development company funded a $42.5 million first tranche at close under a loan and security agreement dated 5 November 2026, which was announced on 10 November. Trinity is administrative agent and collateral agent. Codexis and its wholly owned subsidiary Codexis Mayflower Holdings, LLC are the borrowers.
The facility comprises three tranches. Tranche A was funded at closing. A $7.5 million Tranche B is available at the borrowers’ request through 15 December 2027, subject to customary conditions and a limit that outstanding loan principal, after giving effect to the draw, does not exceed 20% of Codexis’s market capitalisation. A $10.0 million Tranche C is available through the end of the interest-only period, subject to lender approval.
Codexis used the Tranche A proceeds, together with cash on hand, to repay all outstanding obligations under its February 2024 loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, as collateral agent, and the lenders party to that agreement. The repayment totalled approximately $43.6 million, covering principal, accrued and unpaid interest, a prepayment fee, a final payment fee and other fees and expenses. The Innovatus obligations were satisfied and discharged, liens were released and the agreement was terminated, while warrants previously issued to Innovatus remain outstanding. Codexis said that, following the closing, it had $42.5 million of outstanding debt.
The Innovatus facility was a five-year term loan of up to $40.0 million, with $30.0 million funded in February 2024 and $10.0 million funded in June 2025 after milestone achievement. It was scheduled to mature in February 2029 and had an interest-only period through 1 February 2027, extendable to 1 February 2028 on financial milestones.
The Trinity loan bears interest at a variable annual rate equal to the greater of 10.50% and the sum of the lesser of The Wall Street Journal prime rate and 8.00%, plus 3.75%. The loans carry a 1.00% commitment fee on each funded principal amount and a 5.00% end-of-term payment on original principal funded, payable at maturity or on earlier prepayment or acceleration.
Monthly interest-only payments run until 1 November 2030, followed by equal monthly principal and interest instalments through the 1 November 2031 maturity. If no event of default or potential event of default has occurred by the end of the interest-only period, the interest-only period extends to maturity. Whole-loan prepayment premiums are 3.00% on or before the first anniversary of closing, 2.00% after the first anniversary and on or before the second, and 1.00% thereafter.
The loan is secured by substantially all assets, including intellectual property, subject to customary exceptions. Codexis must maintain liquidity of at least the outstanding principal amount of the loans whenever its market capitalisation is below $400.0 million, subject to a 60-day cure right that can be used no more than twice in any trailing 12-month period and is unavailable if liquidity falls below 90% of outstanding principal.
Trinity also received warrants to purchase up to 1,666,668 Codexis shares at $1.08 per share. Warrants vest as each tranche is funded in an amount equal to 3.0% of funded principal divided by the exercise price. On the Tranche A funding, warrants vested for 1,180,556 shares. They expire on 5 November 2036 and may be exercised on a cashless basis.
Codexis, based in Redwood City, California, provides enzymatic solutions for therapeutics manufacturing. It is developing its ECO Synthesis Manufacturing Platform, an aqueous enzymatic process for oligonucleotide manufacturing initially aimed at RNAi and siRNA therapeutics, and supplies enzymes through its BioCatalysis business for small molecule therapeutics manufacturing.
Georgia Erbez, chief financial officer and chief business officer of Codexis, said: “This refinancing enhances our financial position as we look ahead to executing on our upcoming key milestones.”
For the quarter ended 30 June 2026, Codexis reported total revenue of $14.9 million and a net loss of $12.0 million. It had $54.9 million of cash, cash equivalents and short-term investments at quarter-end, and later said a July 2026 public offering of common stock raised approximately $25 million in net proceeds, resulting in pro forma cash of approximately $80 million.
As of 30 June 2026, Trinity Capital had deployed more than $6.2 billion across over 490 investments since inception in 2008.